Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by MineDiggeron Jul 12, 2021 6:02am
180 Views
Post# 33528826

RE:RE:RE:RE:RE:RE:New article

RE:RE:RE:RE:RE:RE:New articleWell Chrispi certainly has "opened his mouth", several times, I'm still trying to work out how his "end of the movie explanation" comment about me is in any way analogous to my wanting to avoid watching a repeat.
 
Despite all you keep on saying Chrispi, the fact remains that we had an NR which gave minimal details of some new MS research results, one of our much awaited data readouts (but no actual data). That MS NR was followed immediately by the release of a video interview with the CEO. In that context, especially given the delays, most CEOs would be eager to use the opportunity to put some flesh on the NR to help make the significance and potential clearer. DrDJ failed to do that (didn't even mention it in fact), despite however much we are paying in IR/PR costs for advice and promotion nowadays. I was very unimpressed. 
 
I still say it was very reasonable to post a heads-up so that anyone looking for further insight into the MS NR, be they new or old investors, would know there was no point in wasting their time on watching that video, or the other shorter video, or reading that NR rehash. I'm surprised you and many other shareholders don't expect better communications from the company, especially those that have invested so much more recently.
 
Chrispi, perhaps you could give up on the personal insult stuff, it poisons the bullboard in exactly the way you should be avoiding if you want people who come here to learn good things about Bioasis, and should be beneath you. I see you have become very much a jd clone, in that you put so much effort into belittling anyone who dares say something you don't approve off.
 
Thinking further about new eyes on Bioasis, the CP has not been updated since late March and still hasn't had those Q1 missed dates adjusted (a full Q late), let alone any update to reference the new MS NR. As you apparently have lots of time available to read and watch duplicated material and to post snide comments about other shareholders, could you consider using some of it to ask Bioasis for an update? At least they have corrected that typo in the version of the MS NR on the website. You could even ask them why they haven't published more detail about it.
 
MD
<< Previous
Bullboard Posts
Next >>